Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

1. Pernas, S.
2. Gil-Gil, M.
3. De Olza, M.O.
4. Gumà, A.
5. Climent, F.
6. Petit, A.
7. Pla, M.J.
8. García-Tejedor, A.
9. López-Ojeda, A.
10. Falo, C.
11. Fernandez-Otega, A.
12. Mesia, C.
13. Pérez-Martin, F.J.
14. Urruticoechea, A.
15. Germà, J.R.